Carboxypeptidase B2 (CPB2), also known ascarboxypeptidase U (CPU),plasma carboxypeptidase B (pCPB) orthrombin-activatable fibrinolysis inhibitor (TAFI), is anenzyme that, in humans, is encoded by thegeneCPB2.[5][6]
CPB2 is synthesized by the liver[7] and circulates in the plasma as aplasminogen-boundzymogen. When it is activated by proteolysis at residue Arg92 by thethrombin/thrombomodulin complex, CPB2 exhibits carboxypeptidase activity. Activated CPB2 reduces fibrinolysis by removing thefibrinC-terminal residues that are important for the binding and activation ofplasminogen.[8][9]
Carboxypeptidases are enzymes that hydrolyze C-terminal peptide bonds. The carboxypeptidase family includes metallo-, serine, and cysteine carboxypeptidases. According to their substrate specificity, these enzymes are referred to as carboxypeptidase A (cleaving aliphatic residues) or carboxypeptidase B (cleaving basic amino residues). The protein encoded by this gene is activated bythrombin and acts on carboxypeptidase B substrates. After thrombin activation, the mature protein downregulatesfibrinolysis.[10]
Fibrinolysis (simplified). Blue arrows denote stimulation, and red arrows inhibition.
Polymorphisms have been described for this gene and its promoter region. Available sequence data analyses indicate splice variants that encode different isoforms.[10]
^Tsai SP, Drayna D (Dec 1992). "The gene encoding human plasma carboxypeptidase B (CPB2) resides on chromosome 13".Genomics.14 (2):549–50.doi:10.1016/S0888-7543(05)80268-X.PMID1427879.
^Kaushansky K, Lichtman M, Beutler E, Kipps T, Prchal J, Seligsohn U. (2010; edition 8: pages 1833-1834 and 2040-2041)Williams Hematology. McGraw-Hill.ISBN978-0071621519
^Zhao L, Morser J, Bajzar L, Nesheim M, Nagashima M (December 1998). "Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms".Thromb. Haemost.80 (6):949–55.doi:10.1055/s-0037-1615394.PMID9869166.S2CID1803078.
^Boffa MB, Reid TS, Joo E, Nesheim ME, Koschinsky ML (May 1999). "Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B)".Biochemistry.38 (20):6547–58.doi:10.1021/bi990229v.PMID10350473.
Vanhoof G, Wauters J, Schatteman K, et al. (1997). "The gene for human carboxypeptidase U (CPU)--a proposed novel regulator of plasminogen activation--maps to 13q14.11".Genomics.38 (3):454–5.doi:10.1006/geno.1996.0656.PMID8975730.
Matsumoto A, Itoh K, Matsumoto R (2000). "A novel carboxypeptidase B that processes native beta-amyloid precursor protein is present in human hippocampus".Eur. J. Neurosci.12 (1):227–38.doi:10.1046/j.1460-9568.2000.00908.x.PMID10651877.S2CID26058321.
Mosnier LO, Lisman T, van den Berg HM, et al. (2002). "The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration".Thromb. Haemost.86 (4):1035–9.doi:10.1055/s-0037-1616530.PMID11686321.S2CID4080586.
Mosnier LO, Meijers JC, Bouma BN (2002). "The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis".Thromb. Haemost.86 (4):1040–6.doi:10.1055/s-0037-1616531.PMID11686322.S2CID21500722.
Mosnier LO, Elisen MG, Bouma BN, Meijers JC (2002). "Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation".Thromb. Haemost.86 (4):1057–64.doi:10.1055/s-0037-1616533.PMID11686324.S2CID32258311.
Morange PE, Aillaud MF, Nicaud V, et al. (2002). "Ala147Thr and C+1542G polymorphisms in the TAFI gene are not associated with a higher risk of venous thrombosis in FV Leiden carriers".Thromb. Haemost.86 (6):1583–4.doi:10.1055/s-0037-1616769.PMID11776333.S2CID30051401.
Koschinsky ML, Boffa MB, Nesheim ME, et al. (2002). "Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAF1) with blood pressure".Clin. Genet.60 (5):345–9.doi:10.1034/j.1399-0004.2001.600504.x.PMID11903334.S2CID86724521.
Antovic JP, Blombäck M (2003). "Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation".Thromb. Res.106 (1):59–62.doi:10.1016/S0049-3848(02)00072-5.PMID12165290.
